Overview

the Incidence of Necrotizing Enterocolitis in Preterm With Respiratory Distress Syndrome Undergoing Caffeine Therapy

Status:
Active, not recruiting

Trial end date:
2024-07-30

Target enrollment:
0

Participant gender:
All

Summary

It is a randomized, prospective study; it will be carried out in the NICU at Alzahraa University Hospital including 50 newborn babies diagnosed with respiratory distress syndrome. The purpose of this study is to : 1. Investigate the protective caffeine on necrotizing enterocolitis in respiratory distress syndrome preterm infants. 2. Detect the impact of caffeine protocol treatment on the in-incidence of necrotizing enterocolitis in respiratory distress syndrome preterm infants in neonatal intensive care 1- Control group It includes preterm infants with respiratory distress syndrome aged 32 weeks-35 weeks. 2- Caffeine-treated group It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.

Phase:

Early Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Al-Azhar University

Treatments:

Amikacin
Caffeine
Caffeine citrate

Criteria

Inclusion Criteria:

- All preterm infants with respiratory distress syndrome.

Exclusion Criteria:

- Preterm admitted to NICU for other reasons rather than respiratory distress

- Major congenital anomalies

- spontaneous intestinal perforation

- Endocrinal Dysfunctions